Pharma News: VIVUS, Inc. (VVUS)’s Injury, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Agreement

Amgen’s $9.5-bn Onyx deal stumbles over cancer drug data (Domain-B)
An agreed takeover of biotechnology company Onyx Pharmaceuticals Inc by its larger peer Amgen, Inc. (NASDAQ:AMGN) has been stalled over a dispute on access to data from an ongoing drug trial of Onyx’s new blood cancer drug. …Onyx has agreed to accept a raised $130-a-share all-cash offer from Amgen but the deal has stalled on whether Onyx will provide Amgen, Inc. (NASDAQ:AMGN) with data from a study designed for European approval of Onyx’s blood-cancer treatment Kyprolis, Bloomberg today reported, citing three people familiar with the matter. Onyx does not have access to the data since the trial is ongoing and is not keen to obtain results before the study is over as it may slow the approval process, the report said.

Hot Biotech Stocks (TheREM)
Athersys, Inc. (NASDAQ:ATHX) surged 9.25% on Thursday after news that it will present at the third annual Regen Med Partnering Forum to be held on October 14 and 15, 2013 at the Estancia La Jolla Hotel & Spa, La Jolla, California as part of the SCMOM. …Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed high volatility as investors were keeping their eyes on the prescription numbers from IMS Health followed by the Symphony Health numbers.